SCARB1 and Hypercholesterolemia: Since we do not detect changes in ApoA-I levels, we could speculate either that longer rosuvastatin treatment periods are required to induce potential changes in this apolipoprotein or that hypercholesterolemia, per se, may induce alterations in the main cholesterol efflux receptors, ABCA1 (ABCG1 and SR-B1), that are not reverted after a 30-day rosuvastatin treatment.